Severity
Low
FDA Drug recall · Reported November 9, 2016
Subpotent Drug; Ethinyl Estradiol
Par Pharmaceutical, Inc. recalled Gildess FE 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, … - a low-severity action.
Gildess FE 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, … was recalled by Par Pharmaceutical, Inc. in November 9, 2016. Reason: Subpotent Drug; Ethinyl Estradiol. Check the official notice for the remedy. Verify recall #D-0122-2017 with the FDA Drug before acting.
The recall
Par Pharmaceutical, Inc. issued this low-severity FDA Drug recall-Subpotent Drug; Ethinyl Estradiol.
Sourced from official FDA Drug enforcement records. Verify recall #D-0122-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0122-2017) was formally reported on November 9, 2016, with the manufacturer initiating the action on September 27, 2016. It is classified under Low severity (Class III), with a current status of Completed. Par Pharmaceutical, Inc. is listed as the recalling firm, operating out of Chestnut Ridge, NY. Federal records list the affected scope as 278,406 tablets.
The documented reason for this recall is: Subpotent Drug; Ethinyl Estradiol Distribution data in the federal record shows the product reached: Nationwide and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
278,406 tablets
Related Recalls
6
5 from same agency
Gildess FE 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, USP and ferrous fumarate tablets, USP 75 mg), 6 blisters (28 count), NDC 0603-7608-17, Rx only, Manufactured in Canada By: Patheon, Inc., Ontario, Canada L5N 7K9, Manufactured for QUALITEST PHARMACEUTICALS, USA, Huntsville, AL 35811
Subpotent Drug; Ethinyl Estradiol
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Completed |
| Recall number | D-0122-2017 |
| Date reported | November 9, 2016 |
| Date initiated | September 27, 2016 |
| Recalling firm | Par Pharmaceutical, Inc. |
| Firm location | Chestnut Ridge, NY |
| Affected scope | 278,406 tablets |
| Distribution | Nationwide and Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 9, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.